Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer. Anchoori RK, Tseng SH, Tsai HL, Palande V, et al. PLoS One 2024;19:e0305710.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Anchoori RK, Tseng SH, Tsai HL, Palande V, et al. Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer. PLoS One 2024;19:e0305710.
PMID: 38990850